The favorable pharmacokinetic characteristics in the tumor, specifically the 5 %ID/g peak concentration (Cmax) 1.5–2 h after administration (Tmax) and the longevity of the uptake in the tumor (T1/2), which led to the tumor exhibiting higher accumulation (AUC) than all organs other than the kidneys, define [68Ga]PSMA-11 as a good diagnostic radiopharmaceutical for prostate cancer. Here, FOLH1 is linked to prostate carcinoma.